Kainos Medicine, Inc.

Pipeline Development-stage programs in HIV and Dry Mouth
Dry Mouth KM552 formulated as an oral rinse, belongs to a pharmacological class of molecules that potently inhibit the transport of sodium through epithelial sodium channels (ENaC). Blocking ENaC receptors in the mouth is expected to prevent aborption of water and preserve the mouth's hydration level.
HIV KM023 belongs to the class of anti-HIV agents known as non-nucleoside reverse transcriptase inhibitors (NNRTI).

Kainos Medicine, Inc. a privately held research and development company with operations in Seoul, Korea and Morrisville, North Carolina is focused on the discovery and development of breakthrough treatments for cancer, metabolic and infectious diseases.

Upcoming Events

2012 BIO International Convention

June 18-21, 2012 Boston, MA

25th Annual HIV/AIDS on the Front Line Conference

April 25, 2012 University of California Irvine Irvine, CA, USA

EASL International Liver Conference

April 18-22, 2012 Centre Convencions Internacional (CCIB) Barcelona, Spain

Latest News

Sodium Channel Blocker (KM552) for Xerostomia (Dry Mouth) in patients with Sjogren’s Disease.

The xerostomia project received a grant from the Korean government in October 2008 as it was chosen as a Bio Star Project. The Bio Star Project intends to support the Korean pharmaceutical companies’ effort in developing new drugs, especially drugs in clinical development.